Prime Medicine（Prime Medicine, Inc.）今日宣布，美国食品药品监督管理局（FDA）已批准其针对H1069q突变型威尔逊病候选药物Pm577a的研究性新药申请（IND）。这一里程碑式的进展，标志着该公司在基因编辑疗法领域迈出了关键一步。
Prime Medicine（Prime Medicine, Inc.）今日宣布，美国食品药品监督管理局（FDA）已批准其针对H1069q突变型威尔逊病候选药物Pm577a的研究性新药申请（IND）。这一里程碑式的进展，标志着该公司在基因编辑疗法领域迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.